J P Morgan Chase & Co reaffirmed their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a research note issued to investors on Monday. J P Morgan Chase & Co currently has a $190.00 price target on the specialty pharmaceutical company’s stock.

Several other research analysts also recently weighed in on JAZZ. Cowen and Company reiterated an outperform rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Wells Fargo & Company reiterated an outperform rating and issued a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Piper Jaffray Companies reiterated a buy rating and issued a $177.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Royal Bank Of Canada reiterated a buy rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Friday, September 15th. Finally, Janney Montgomery Scott reiterated a buy rating and issued a $192.00 price target (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC presently has an average rating of Buy and a consensus target price of $180.96.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 147.78 on Monday. The firm has a market cap of $8.88 billion, a PE ratio of 22.76 and a beta of 1.13. The firm’s 50-day moving average price is $148.82 and its 200 day moving average price is $150.52. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The business had revenue of $394.39 million during the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.67 earnings per share. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-given-buy-rating-at-j-p-morgan-chase-co/1579611.html.

In other Jazz Pharmaceuticals PLC news, SVP Paul Treacy sold 1,304 shares of the company’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $143.32, for a total value of $186,889.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $160.00, for a total transaction of $732,800.00. Following the completion of the transaction, the executive vice president now directly owns 32,322 shares of the company’s stock, valued at $5,171,520. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,297 shares of company stock valued at $1,279,417. 4.30% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of JAZZ. Intl Fcstone Inc. bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $230,000. Toronto Dominion Bank lifted its position in shares of Jazz Pharmaceuticals PLC by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 81 shares during the last quarter. WINTON GROUP Ltd bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $433,000. GRATRY & Co LLC lifted its position in shares of Jazz Pharmaceuticals PLC by 121.6% during the second quarter. GRATRY & Co LLC now owns 17,040 shares of the specialty pharmaceutical company’s stock worth $2,650,000 after purchasing an additional 9,350 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter worth about $1,959,000. 88.24% of the stock is owned by institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.